Leuprorelin acetate, also called leuprolide acetate, is a gonadotropin-releasing hormone (GnRH) agonist used in specialist hormone treatment. Medicine identity.
This guide covers prostate cancer and selected breast-cancer uses; product-specific instructions and specialist decisions remain essential.
- Acetate names match; products differ.
- Early flare: new neurological or urinary symptoms need immediate review.
- SR and Prostap 3 differ in ovarian preservation.
- Stopped periods are not contraception; coordinate endocrine-treatment changes.
- English community items measure dispensing, not individual outcomes or worldwide popularity.
Table of contents
- Evidence summary
- Names and salts
- Hormone suppression and flare
- Specialist uses
- Symptoms, bones and supplements
- England dispensing volume and independent evidence limits
- Urgent symptoms
- Medicine interactions
- Pregnancy/breastfeeding
- Preparation and monitoring
- Animal evidence
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical descriptions, care guidance and independently established treatment outcomes have different evidentiary roles. The table identifies what the reviewed sources can support and which financial or clinical questions remain unresolved.
| Question / approach | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| Active names | NCI entries | Page receipts unclosed | Acetate versus mesylate. |
| Care context | NCI education | Original trials unclosed | Attributed guidance. |
| Product labels | Licences/safety | Seller | Efficacy excluded. |
| Preparation | MHRA | Industry-fee route | Professional handling. |
| Emergency assessment | NICE/NHS | Reviewer payments unclosed | Triage. |
| Dispensing | England PCA | Agency routes disclosed | Not patients/worldwide use. |
Names and salts
US acetate brands include Eligard and Lupron Depot. The NCI entry describes palliative treatment of advanced prostate cancer. US acetate scope. Palliative care addresses disease and symptoms; it is not a claim that the cancer has been cured.
Camcevi contains leuprolide mesylate. Different salt. This article does not convert salts or add Camcevi use to acetate prescribing counts.
Depots release medicine over time. Identity.
Confirm product instructions with the administering service.
Hormone suppression and flare
Leuprolide acts at pituitary GnRH receptors; sustained use inhibits follicle-stimulating hormone (FSH) and luteinising hormone (LH), reducing testosterone or oestradiol production. Pituitary mechanism.
Agonists initially increase testosterone before suppression. This flare can worsen bone pain, urinary blockage or spinal-cord compression. GnRH antagonists act differently and do not cause the same initial surge. Class distinction.
Specialist uses
Prostap 3 lists metastatic/locally advanced prostate cancer, specified higher-risk use alongside radiotherapy or after prostatectomy, and selected pre/perimenopausal breast-cancer settings. UK indications.
Castration-resistant disease progresses despite low testosterone; ongoing androgen-deprivation treatment can remain part of specialist combination care. Progression and continued ADT.
Breast endocrine care depends on tumour ER/PR (oestrogen/progesterone receptor) results. GnRH agonists suppress functioning ovaries; aromatase inhibitors in premenopausal women require ovarian suppression. NCI also describes GnRH use with an aromatase inhibitor in men with advanced breast cancer. Distinct clinical contexts. A US educational description does not establish every UK product licence.
SR includes chemotherapy-related ovarian preservation, without replacing fertility-preservation methods. Prostap 3 excludes this use. SR scope Product exclusion.
Symptoms, bones and supplements
The Christie describes hot flushes, vaginal dryness, reduced libido, mood changes and joint/muscle symptoms. Layers and nonhormonal lubricants may help comfort. Report persistent depression or difficult symptoms; review menopause remedies and herbal products first. Dated breast-care support.
Androgen deprivation can affect bone, muscle, sexual function and metabolism. Class-level effects.
Tell the cancer team about complementary products; they should not replace or delay treatment. Disclosure and non-replacement safety. No independently established supplement benefit for this drug is demonstrated here.
England dispensing volume and independent evidence limits
FY2025/26 England data record 259,352 leuprorelin-acetate prescription items, BNF code 0803042N0, in the original chemical-substance table. Actual row 1033.
PCA describes community dispensing in England. Publication setting.
Hospital-issued prescriptions fulfilled in the community are included; hospital dispensary supplies are excluded. Individual indications are not recorded. Original coverage methods.
Items are not unique people, doses or proof of benefit. The BNF malignant-disease grouping cannot separate each person’s cancer prescription from another indication. This guide reports attributed care and regulated warnings; it does not present an independently finance-cleared head-to-head trial verdict or rank brands.
Urgent symptoms
In a person with cancer, new weakness, walking difficulty, numbness or bladder/bowel dysfunction can indicate cord compression. NICE treats these signs as an oncology emergency: seek immediate specialist or emergency assessment. Primary emergency-recognition guidance.
With SR, worsening leg pain/weakness or urinary difficulty needs immediate medical contact. Blistering, peeling or mucosal ulcers require immediate care and stopping further use pending assessment. Urgent patient warnings.
Call 999 or your local emergency number for sudden throat/tongue swelling, breathing difficulty or collapse suggesting anaphylaxis. Severe allergy action.
Severe breathlessness, chest/upper-back pain or a very fast heartbeat requires emergency assessment; do not drive yourself. Pulmonary-embolism triage.
Call 999 or your local emergency number for an ongoing seizure. Immediate seizure action.
Report seizures, depressed mood, or severe/recurrent headache with visual symptoms or ringing ears urgently. Neurological and mood precautions.
Medicine interactions
SR reports no formal interaction studies. In men, review QT-risk medicines, including amiodarone, sotalol, methadone, moxifloxacin and antipsychotics. Interaction precautions.
A prolonged QT interval is an ECG pattern associated with heart-rhythm problems. Electrical-pattern context. Absence of interaction studies is not proof that combinations are safe.
Confirm ovarian suppression before starting an aromatase inhibitor, then maintain it; interruption needs coordinated clinical review. Combined-treatment precaution.
Pregnancy/breastfeeding
SR is contraindicated during pregnancy/breastfeeding. Possible pregnancy needs immediate prescriber contact before further injection. Pregnancy/feeding warning.
The Christie emphasises that stopped periods are not contraception; arrange nonhormonal precautions with the treating team. Contraceptive distinction. Confirm after-treatment precautions rather than adopting an old fixed interval.
Diabetes, heart problems and depression history need clinical review. Suitability review.
Preparation and monitoring
MHRA reported depot handling errors potentially reducing effectiveness. Preparation, reconstitution and administration require professionals familiar with the exact product; multistep systems need particular care. Dated handling alert. Do not improvise mixing or injection technique.
For a missed Prostap SR injection, contact the doctor as soon as you realise. Missed-injection instruction. Do not arrange a double or substitute depot yourself.
Prostap 3 prostate monitoring includes clinical review, PSA (prostate-specific antigen) and testosterone measurements. Response monitoring.
Keep product/last-injection records; confirm appointments and after-hours contact.
Animal evidence
Prostap 3 reports reproductive harm in animals. Preclinical.
Animal findings cannot quantify an individual human risk or establish human treatment benefit; no animal or cell-study efficacy enters this verdict.
UK filings report Takeda Pharmaceutical Company Limited as the controlling parent of Takeda UK. Actual ownership filing. The parent’s revised earnings report records medicine sales, including LEUPLIN/ENANTONE, and bonds/loans. It explicitly says this earnings report is audit-exempt. Current financial original.
Takeda reports its global HQ in Tokyo. Current corporate identity. This is one holder’s trace, not an audit of every generic, manufacturer or shareholder worldwide. Seller information remains useful for identified product warnings; it is excluded from an independent efficacy conclusion.
Funding and source roles
Research funding at a glance
32 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
The source-specific map separates documented institutional funding from disease-page payments and trial sponsorship. Unknown allocations remain unknown. A public agency, charity or academic address does not by itself establish independent treatment efficacy.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NCI: drug dictionary | Public/gift routes below; page/reviewer/trial receipts unknown. | United States; Bethesda. | Tier 2, provisional. | C — date unexposed; clinical accountability. |
| NCI: acetate | Public/gift routes below; page/reviewer/trial receipts unknown. | United States; Bethesda. | Tier 2, provisional. | C — 27 September 2024; clinical accountability. |
| NCI: mesylate | Public/gift routes below; page/reviewer/trial receipts unknown. | United States; Bethesda. | Tier 2, provisional. | C — 17 January 2025; clinical accountability. |
| NCI: prostate hormone therapy | Public/gift routes below; page/reviewer/trial receipts unknown. | United States; Bethesda. | Tier 2, provisional. | C — 4 October 2024; clinical accountability. Intermittent-trial statement excluded. |
| NCI: breast hormone therapy | Public/gift routes below; page/reviewer/trial receipts unknown. | United States; Bethesda. | Tier 2, provisional. | C — 23 September 2026; clinical accountability. |
| Prostap SR SmPC | Takeda; parent/revenue below. | UK; London. | Tier 4 seller. | D — June 2025; licence/safety, efficacy excluded. |
| Prostap 3 SmPC | Takeda; finance below. | UK; London. | Tier 4 seller. | D — June 2025; safety. |
| Prostap SR leaflet | Takeda; finance below. | UK; London; manufacturer Cerano, Italy. | Tier 4 seller. | D — June 2025; safety. |
| Christie: goserelin/leuprorelin leaflet | Trust accounts below; author/trial receipts unknown. | UK; Manchester. | Tier 2, provisional. | C — April 2023, April 2026 deadline passed; care accountability. Goserelin flare, universal vaccines and old timelines excluded. |
| MHRA: depot handling alert | Industry-fee/public institutional routes below; holder-origin letter and alert-specific receipts not independently cleared. | United Kingdom; MHRA. | Tier 3 regulatory context with industry-fee route. | C, provisional — 26 August 2020. Safety accountability; no quantitative effectiveness estimate. |
| NHS: long QT syndrome | National policy below; named page/reviewer and original-study payments unclosed. | United Kingdom; national website. | Tier 2 safety education, provisional. | C, provisional — 6 January 2025. Clinical accountability; no drug-event incidence or inherited-disease diagnosis inferred. |
| NICE NG234: cord-compression recognition | Institutional finance below; committee interests and original studies unclosed. | United Kingdom; NICE, Manchester/London. | Tier 2 clinical guidance, provisional. | C, provisional — 6 September 2023. Actual indexed primary recommendations 1.3 read; direct body 403. No treatment regimen inferred. |
| NICE: 2025/26 accounts | Primarily DHSC grant-in-aid; NHS England support; appraisal/advice fees, commercial income and research. NG234 allocation unknown. | United Kingdom; 3 Piccadilly Place, Manchester M1 3BN; London office. | Tier 3 financial report. | B, provisional — saved original selected pages 30–31 read; fresh oversized retrieval failed. Financial accountability, assessment-income interests; no committee/trial clearance. |
| Companies House: Takeda UK control | Active Takeda Pharmaceutical Company Limited, Japan: at least 75% shares/votes and director-appointment rights. | United Kingdom filing; parent registered Osaka, Japan. | Tier 3 statutory filing, provisional. | C, provisional — notified 6 April 2016, current active record read. Filing accuracy not independently verified; ultimate shareholders and product allocations unclosed. |
| Takeda: revised FY2025 earnings filing | Medicine sales, including LEUPLIN/ENANTONE; bonds, bilateral and syndicated loans and operating cash flow. | Japan parent; global sales; US SEC filing. | Tier 4 commercial financial self-report. | D for independence — revised 5 June 2026, year ended 31 March. Audit-exempt report; exact label/trial receipts unclosed; no clinical claims adopted. |
| Takeda integrated report | Revenue/debt separately traced. | Japan; global HQ 1-1 Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8668. | Tier 4. | D — selected 2026 identity/footer; promotion excluded. |
| The Christie: 2025/26 accounts | NHS commissioner contracts; other/non-NHS activity; R&D, education/services, charity contributions, commercial income and rentals separately recorded. | United Kingdom; NHS foundation trust, Manchester. | Tier 3 institutional financial report. | B, provisional — actual 140-page original, selected notes 1.2/1.9/3 read. Audit supports tracing; every sponsor, clinician and leaflet allocation unclosed. |
| The Christie: report index and address | Same trust; money routes independently documented in its accounts, not inferred from national NHS policy. | United Kingdom; Wilmslow Road, Manchester M20 4BX. | Tier 3 institutional identity self-report. | B, provisional — actual current body/footer read. Public identity accountability; not a medical source or allocation audit. |
| NHS: anaphylaxis | National policy below; individual page/reviewer and original-study payments unclosed. | United Kingdom; national website. | Tier 2 clinical safety context, provisional. | C, provisional — 21 June 2023; 2026 review deadline passed. Clinical accountability supports triage; no leuprorelin-event incidence or efficacy inference. |
| NHS: pulmonary embolism | National policy below; individual page/reviewer and original-study payments unclosed. | United Kingdom; national website. | Tier 2 clinical safety context, provisional. | C, provisional — 25 May 2023; 2026 review deadline passed. Clinical accountability supports triage; no leuprorelin-event incidence or efficacy inference. |
| NCCIH: complementary cancer care | Public/gift originals below; credited White, Olaku, King, Sansevere and Shurtleff personal/page interests unclosed. | United States; NIH/HHS, Bethesda, Maryland. | Tier 2 educational safety context, provisional. | C, provisional — October 2021. Public clinical duties; no leuprorelin-adjunct benefit or blanket supplement safety established. |
| NCI: enacted budget | Congressional appropriations through NIH/HHS; enacted fiscal funding distinguished from forward requests. | United States; federal NCI, Bethesda, Maryland. | Tier 3 institutional financial self-report. | B, provisional — updated 14 May 2026, actual body read. Public budget scrutiny supports accuracy; complete page and trial allocations unclosed. |
| NCI: Gift Fund and address | Voluntary Gift Fund contributions and Breast Cancer Research Stamp route; research designations/company-name field do not establish named page sponsorship. | United States; 9000 Rockville Pike, Bethesda, Maryland 20892. | Tier 3 institutional financial self-report. | B, provisional — 27 August 2025, actual body read. Disclosure/accountability support money tracing; accepted donor receipts and allocation unclosed. |
| NHSBSA: England PCA 2025/26 | Separate agency accounts below; PCA staff/page allocation unclosed. | United Kingdom; England community dispensing. | Tier 2 administrative statistics, provisional. | B, provisional — 4 June 2026. Reimbursement/statistical accountability; no clinical indication or efficacy inference. |
| NHSBSA: original chemical workbook | Same separately documented agency routes; supplier sponsorship not inferred. | United Kingdom; England. | Tier 2 administrative data, provisional. | B, provisional — original Chemical_Substances row 1033: 259,352 items. Not patients, doses, cancer-only or global use. |
| NHSBSA: PCA methodology | Same documented agency routes; analytic contracts unclosed. | United Kingdom; England. | Tier 2 methods disclosure, provisional. | B, provisional — June 2026 scope/limitations selected. Administrative checking favors totals; no cancer-specific indication ranking established. |
| NHSBSA: accounts 2025/26 | Parliamentary DHSC funding; separate full-cost service charges/public repayment work and DHSC student support. NHS SBS investment noted; complete co-ownership unclosed. | United Kingdom; Stella House, Goldcrest Way, Newburn Riverside, Newcastle upon Tyne NE15 8NY. | Tier 3 institutional financial report. | B, provisional — actual 163-page original, selected pages 132–133/143 and address read. Statutory accounting aids reliability; PCA staff/page allocations remain unassigned. |
| NHS national content/funding policy | DHSC funding; no advertising/corporate sponsorship. Staff/external contributors must disclose interests; full named receipts are not published here. | United Kingdom; national website, separate from provider trusts. | Tier 3 financial/editorial self-report. | B, provisional — 14 October 2022; October 2025 review deadline passed. Public accountability favors accuracy; policy is not current provider accounts or trial clearance. |
| MHRA: accounts 2025/26 | Most running costs from statutory industry fees/non-statutory goods/services; separate DHSC funding. Conflict safeguards described; no alert-specific payer assigned. | United Kingdom; DHSC executive agency. | Tier 3 institutional financial report. | B, provisional — actual 186-page original, funding section and financial statements selected. Statutory audit supports money tracing; regulated-industry and access incentives remain. |
| MHRA: official contact/identity | Industry/public routes documented in separate accounts; complete board/contractor interests unclosed. | United Kingdom; 10 South Colonnade, London E14 4PU. | Tier 3 institutional identity self-report. | B, provisional — actual government contact body read. Official address is reliable identity evidence, not proof of independent efficacy. |
| NCCIH: appropriations history | Enacted congressional appropriations reported through FY2024; no FY2026 request treated as enacted or page allocation inferred. | United States; 9000 Rockville Pike, Bethesda, Maryland. | Tier 3 institutional financial self-report. | B, provisional — actual dated fiscal entries read. Public budget scrutiny favors accuracy; complete current receipts and disease-page allocation unclosed. |
| NCCIH: separate Gift Fund route | Authorized voluntary donations/bequests; conditional research-area or unconditional gifts separate from appropriations. Accepted donor receipts unclosed. | United States; NIH/HHS, Bethesda, Maryland. | Tier 3 institutional financial self-report. | B, provisional — actual authority/process read. Disclosure and public accountability favor accuracy; permitted gifts do not establish corporate payment for the safety page. |
Frequently asked questions
Are leuprorelin and leuprolide the same? For acetate, yes: NCI lists leuprorelin acetate as the synonym. Identity. That does not make every depot interchangeable.
Does a lower PSA mean cure or permission to stop? No. Discuss treatment changes with the team.
Does no period mean pregnancy is impossible? No. The contraceptive plan needs confirmation with the treating team. Contraception warning.
Is ovarian suppression the same as removing ovaries? No. NCI distinguishes drug suppression from permanent surgical ovarian ablation. Ovarian-function distinction. Fertility and recovery still need individual discussion.
Does a prescribing count show the best cancer drug? No. It describes a particular dispensing dataset, not personal benefit. The indication is absent. Dataset limits.
Sources and funding notes
Selected primary NICE recognition text was available in the index; direct retrieval returned 403, so no treatment algorithm is supplied. The parent’s oversized full 20-F was not read; selected revised SEC earnings and integrated-report originals were. No sales-growth promotion, numerical outcome, personal dose, depot conversion or pediatric/co-packaged regimen is given. Government education does not clear its original efficacy studies. Known seller material is excluded from the independent outcome verdict.
- NCI: drug dictionary — Synonym and pituitary mechanism.
- NCI: acetate — US names and approved prostate scope.
- NCI: mesylate — Separate salt and Camcevi identity.
- NCI: prostate hormone therapy — Class-level flare, symptoms and care distinctions.
- NCI: breast hormone therapy — Ovarian suppression and hormone-receptor contexts.
- Prostap SR SmPC — Licence and safety distinctions.
- Prostap 3 SmPC — Scope, monitoring, animals.
- Prostap SR leaflet — Pregnancy, missed injections, acute warnings.
- Christie: goserelin/leuprorelin leaflet — Selected breast-care comfort and contraceptive context.
- MHRA: depot handling alert — Professional preparation and error prevention.
- NHS: long QT syndrome — ECG-pattern and rhythm-risk context only.
- NICE NG234: cord-compression recognition — Oncology emergency warning only.
- NICE: 2025/26 accounts — Institutional channels and location only.
- Companies House: Takeda UK control — Reported immediate controlling entity only.
- Takeda: revised FY2025 earnings filing — Commercial sales and borrowing routes only.
- Takeda integrated report — Current global HQ and corporate identity only.
- The Christie: 2025/26 accounts — Selected institutional revenue channels only.
- The Christie: report index and address — Current report link and institutional location.
- NHS: anaphylaxis — Airway swelling/breathing/collapse emergency action.
- NHS: pulmonary embolism — Severe breathing/chest/collapse emergency triage.
- NCCIH: complementary cancer care — Disclosure and non-replacement safety only.
- NCI: enacted budget — Institutional appropriations, not drug-page funding.
- NCI: Gift Fund and address — Separate gift authority/routes only.
- NHSBSA: England PCA 2025/26 — Publication and community setting.
- NHSBSA: original chemical workbook — Leuprorelin-acetate item count/code only.
- NHSBSA: PCA methodology — Community dispensing, hospital-issued prescription and indication limits.
- NHSBSA: accounts 2025/26 — Institutional funding/HQ trace only.
- NHS national content/funding policy — Website funding and editorial safeguards only.
- MHRA: accounts 2025/26 — Regulator-specific funding only.
- MHRA: official contact/identity — Jurisdiction and office only.
- NCCIH: appropriations history — Congressional route and institutional address only.
- NCCIH: separate Gift Fund route — Gift authority, not a named page sponsor.
Educational research reviewed 4 October 2026. Diagnosis and treatment require a qualified clinician; this article does not provide an individual prescription or replace urgent assessment.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.